» Articles » PMID: 2847647

Activity of Fluoroquinolone Antibiotics Against Plasmodium Falciparum in Vitro

Overview
Specialty Pharmacology
Date 1988 Aug 1
PMID 2847647
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The fluoroquinolone antibiotics are structurally related to nalidixic acid. Their primary antibacterial action appears to be mainly due to inhibition of DNA gyrase (DNA topoisomerase II). We determined the activity of several fluoroquinolones in vitro against two strains of Plasmodium falciparum, FCC1 (chloroquine susceptible) and VNS (chloroquine resistant). [3H]hypoxanthine incorporation by malarial parasites was determined at 48 and 96 h. The molarity at which each agent caused a 50% decrease in the incorporation of [3H]hypoxanthine compared with that of drug-free controls was defined as the 50% inhibitory concentration. The fluoroquinolones evaluated were amifloxacin, ciprofloxacin, enoxacin, norfloxacin, ofloxacin, and pefloxacin. Other DNA gyrase inhibitors tested were nalidixic acid, oxolinic acid, novobiocin, and coumermycin A1. Among the fluoroquinolones, ciprofloxacin had the lowest 50% inhibitory concentrations at 48 h against both chloroquine-susceptible and -resistant strains of P. falciparum, (0.26 +/- 0.08) x 10(-4) and (0.38 +/- 0.15) x 10(-4) M, respectively (mean +/- standard deviation). Enoxacin had the lowest 50% inhibitory concentrations against FCC1 and VNS at 96 h, 0.23 x 10(-5) and (0.06 +/- 0.04) x 10(-5) M, respectively. With the VNS strain, fractional inhibitory concentration indexes for the combination of ciprofloxacin and tetracycline were calculated at 48 and 96 h to be 0.93 and 0.79, respectively, indicating modest additive effects. The combination of novobiocin with ciprofloxacin showed indifference in the same system. The antimalarial effects of some fluoroquinolones occur at achievable serum concentrations. Whether inhibition of DNA gyrase contributes to the antimalarial activity of the fluoroquinolones is unknown at present.

Citing Articles

To quest new targets of parasite and their potential inhibitors to combat antimalarial drug resistance.

Biswas P, Roy R, Ghosh K, Nath D, Samadder A, Nandi S J Parasit Dis. 2024; 48(4):671-722.

PMID: 39493470 PMC: 11527868. DOI: 10.1007/s12639-024-01687-x.


Acridine-Based Antimalarials-From the Very First Synthetic Antimalarial to Recent Developments.

Fonte M, Tassi N, Gomes P, Teixeira C Molecules. 2021; 26(3).

PMID: 33498868 PMC: 7865557. DOI: 10.3390/molecules26030600.


Fluorescence Quenching Studies on the Interactions between Chosen Fluoroquinolones and Selected Stable TEMPO and PROXYL Nitroxides.

Zamojc K, Bylinska I, Wiczk W, Chmurzynski L Int J Mol Sci. 2021; 22(2).

PMID: 33477329 PMC: 7830230. DOI: 10.3390/ijms22020885.


Targeting and Inhibiting Using Ultra-small Gold Nanoparticles.

Varela-Aramburu S, Ghosh C, Goerdeler F, Priegue P, Moscovitz O, Seeberger P ACS Appl Mater Interfaces. 2020; 12(39):43380-43387.

PMID: 32875786 PMC: 7586288. DOI: 10.1021/acsami.0c09075.


Repurposing Drugs to Fight Hepatic Malaria Parasites.

Fontinha D, Moules I, Prudencio M Molecules. 2020; 25(15).

PMID: 32731386 PMC: 7435416. DOI: 10.3390/molecules25153409.


References
1.
TRAGER W, Jensen J . Human malaria parasites in continuous culture. Science. 1976; 193(4254):673-5. DOI: 10.1126/science.781840. View

2.
Krogstad D, Schlesinger P . Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. N Engl J Med. 1987; 317(9):542-9. DOI: 10.1056/NEJM198708273170905. View

3.
Cozzarelli N . DNA gyrase and the supercoiling of DNA. Science. 1980; 207(4434):953-60. DOI: 10.1126/science.6243420. View

4.
Desjardins R, Canfield C, Haynes J, Chulay J . Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979; 16(6):710-8. PMC: 352941. DOI: 10.1128/AAC.16.6.710. View

5.
Gellert M . DNA topoisomerases. Annu Rev Biochem. 1981; 50:879-910. DOI: 10.1146/annurev.bi.50.070181.004311. View